JP7623281B2 - 免疫療法で治療されたがん患者の応答の予測を改善する方法 - Google Patents
免疫療法で治療されたがん患者の応答の予測を改善する方法 Download PDFInfo
- Publication number
- JP7623281B2 JP7623281B2 JP2021526801A JP2021526801A JP7623281B2 JP 7623281 B2 JP7623281 B2 JP 7623281B2 JP 2021526801 A JP2021526801 A JP 2021526801A JP 2021526801 A JP2021526801 A JP 2021526801A JP 7623281 B2 JP7623281 B2 JP 7623281B2
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cancer
- loh
- sample
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168315A JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767979P | 2018-11-15 | 2018-11-15 | |
| US62/767,979 | 2018-11-15 | ||
| PCT/US2019/061710 WO2020102674A1 (en) | 2018-11-15 | 2019-11-15 | Method of improving prediction of response for cancer patients treated with immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168315A Division JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513068A JP2022513068A (ja) | 2022-02-07 |
| JP2022513068A5 JP2022513068A5 (cg-RX-API-DMAC7.html) | 2024-03-11 |
| JP7623281B2 true JP7623281B2 (ja) | 2025-01-28 |
Family
ID=70727341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526801A Active JP7623281B2 (ja) | 2018-11-15 | 2019-11-15 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
| JP2024168315A Pending JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168315A Pending JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12497661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3880246A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7623281B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019379167B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120200A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020102674A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116134155A (zh) * | 2020-08-26 | 2023-05-16 | 瑞泽恩制药公司 | 通过施用pd-1抑制剂治疗癌症的方法 |
| CN111979323A (zh) * | 2020-08-28 | 2020-11-24 | 深圳裕策生物科技有限公司 | 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统 |
| CN112029861B (zh) * | 2020-09-07 | 2021-09-21 | 臻悦生物科技江苏有限公司 | 基于捕获测序技术的肿瘤突变负荷检测装置及方法 |
| JP2024516230A (ja) * | 2021-04-30 | 2024-04-12 | ジェネンテック, インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| WO2023196390A1 (en) * | 2022-04-06 | 2023-10-12 | Foundation Medicine, Inc. | Aneuploidy biomarkers associated with response to anti-cancer therapies |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2018132749A1 (en) | 2017-01-13 | 2018-07-19 | The General Hospital Corporation | Resistance to checkpoint blockade therapy |
| WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69933661T3 (de) * | 1998-04-15 | 2012-01-26 | Merck Serono Biodevelopment | Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| EP3327148B1 (en) * | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| KR20170080697A (ko) * | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| MX381241B (es) | 2015-04-27 | 2025-03-12 | Cancer Research Tech Ltd | Composición de células t para usarse en el tratamiento del cáncer. |
| US10563266B2 (en) | 2015-07-14 | 2020-02-18 | Personal Genome Diagnostics Inc. | Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017151524A1 (en) * | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods and systems for evaluating tumor mutational burden |
| US20190247435A1 (en) | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| US20190240257A1 (en) | 2016-10-13 | 2019-08-08 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| AU2018338441B2 (en) * | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
-
2019
- 2019-11-15 CA CA3120200A patent/CA3120200A1/en active Pending
- 2019-11-15 US US16/685,439 patent/US12497661B2/en active Active
- 2019-11-15 AU AU2019379167A patent/AU2019379167B2/en active Active
- 2019-11-15 EP EP19885138.8A patent/EP3880246A4/en active Pending
- 2019-11-15 JP JP2021526801A patent/JP7623281B2/ja active Active
- 2019-11-15 WO PCT/US2019/061710 patent/WO2020102674A1/en not_active Ceased
-
2024
- 2024-09-27 JP JP2024168315A patent/JP2025000809A/ja active Pending
-
2025
- 2025-11-14 US US19/389,414 patent/US20260071282A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2018132749A1 (en) | 2017-01-13 | 2018-07-19 | The General Hospital Corporation | Resistance to checkpoint blockade therapy |
| WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019379167B2 (en) | 2026-05-14 |
| JP2025000809A (ja) | 2025-01-07 |
| EP3880246A1 (en) | 2021-09-22 |
| CA3120200A1 (en) | 2020-05-22 |
| US20200157642A1 (en) | 2020-05-21 |
| EP3880246A4 (en) | 2022-08-10 |
| JP2022513068A (ja) | 2022-02-07 |
| US12497661B2 (en) | 2025-12-16 |
| WO2020102674A1 (en) | 2020-05-22 |
| AU2019379167A1 (en) | 2021-06-03 |
| US20260071282A1 (en) | 2026-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260071282A1 (en) | Method of improving prediction of response for cancer patients treated with immunotherapy | |
| Castelli et al. | A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution | |
| Ahn et al. | The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression | |
| Biran et al. | The genetics of alopecia areata: new approaches, new findings, new treatments | |
| Pagadala et al. | Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response | |
| AU2019346023B2 (en) | Method for selecting neoepitopes | |
| Klaver et al. | Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes | |
| KR102770755B1 (ko) | 바이러스 네오에피토프 및 이의 용도 | |
| US20220154295A1 (en) | Methods and materials for assessing and treating cancer | |
| WO2020221783A1 (en) | Methods for pre-selection of neoepitopes | |
| Wu et al. | Identification of clonal neoantigens derived from driver mutations in an EGFR-mutated lung cancer patient benefitting from anti-PD-1 | |
| JP2025019066A (ja) | 癌の免疫療法のための複合バイオマーカー | |
| JP2025066133A (ja) | マイクロサテライト不安定性シグネチャー | |
| Yan et al. | Causal impact of immune phenotypes on herpes zoster and postherpetic neuralgia: Insights from Mendelian randomization analysis | |
| Gong et al. | Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy | |
| Gillespie et al. | Genomic modifiers of natural killer cells, immune responsiveness and lymphoid tissue remodeling together increase host resistance to viral infection | |
| Zhong et al. | The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs | |
| Goli et al. | Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy | |
| Hou et al. | Rational discovery of response biomarkers: candidate prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy | |
| US20220296642A1 (en) | Methods of Making Therapeutic T Lymphocytes | |
| Spassova | Prognostic and predictive biomarkers in Merkel cell carcinoma | |
| Klaver et al. | In contrast to other Soft tissue sarcomas, GIST shows enhanced numbers of immune check-point-negative CD8 T cells | |
| Rawal et al. | Major Histocompatibility Complex Dmα/β Genes and Their Expressional Diversity in Healthy and Diseased Water Buffalo Bubalus bubalis | |
| Manguso | In Vivo Genetic Screening to Identify Mechanisms of Resistance to Cancer Immunotherapy | |
| HK40013532A (en) | Ranking system for immunogenic cancer-specific epitopes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220928 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230830 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240927 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241008 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7623281 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |